Atlas Trials

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Clinical trial NCT05003700 · COMPLETED

Trial details

NCT number
NCT05003700
Sponsor
Nanfang Hospital, Southern Medical University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2021-08-12
Primary completion
2023-05-26
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.